Form 4: ARS Pharmaceuticals Director Acquires Stock Options

Peter A. Thompson, a Director at ARS Pharmaceuticals, Inc., acquired 30,000 stock options with an exercise price of $10.54.

Summary

• Peter A. Thompson, a Director at ARS Pharmaceuticals, Inc. (SPRY), acquired 30,000 stock options on June 24, 2026.
• The stock options have an exercise price of $10.54 per share.
• These options represent the right to buy common stock and are exercisable until June 23, 2036.
• The underlying securities are 30,000 shares of common stock.
• Thompson's beneficial ownership of these securities is direct.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director rather than a significant new development or financial event.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of 30,000 options indicates a significant stake in potential future equity value.

Risks

• The vesting of the options is contingent on future events, specifically full vesting on June 24, 2027, or the Issuer's 2027 annual meeting of stockholders, the date of which is not yet set.
• There is an obligation for Thompson to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will then provide them to OrbiMed Private Investments VI, LP.

Future Outlook

The future outlook is tied to the vesting and potential exercise of the acquired stock options, which are subject to specific conditions and transfer obligations.

Industry Context

StockSavvy.ai notes that director stock option grants are a common form of executive compensation and incentive within the biopharmaceutical industry, aligning management's interests with those of shareholders.

Related Party Transactions

• Peter A. Thompson is obligated to transfer any securities issued under stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns management interests with shareholder value, though the transfer obligation to OrbiMed entities adds a layer of complexity.
• Management/Employees: Standard compensation practice, reinforcing incentive structures.
• Creditors/Suppliers: No direct impact indicated.

Next Steps

• Vesting of the stock options on June 24, 2027, or the date of the Issuer's 2027 annual meeting of stockholders.
• Potential exercise of stock options by Peter A. Thompson.
• Transfer of securities or economic benefits to OrbiMed entities as per agreement.

Key Dates

Keywords

ARS Pharmaceuticals, SPRY, Form 4, Stock Options, Director, Beneficial Ownership, Peter A. Thompson, SEC Filing, Equity